UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

Allergy (Copenhagen), 2015-10, Vol.70 (10), p.1319-1328

2015

Volltextzugriff (PDF)

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

Annals of allergy, asthma, & immunology, 2023-11, Vol.131 (5), p.S5

2023

Volltextzugriff (PDF)

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

Annals of allergy, asthma, & immunology, 2023-11, Vol.131 (5), p.S5-S5

2023

Volltextzugriff (PDF)

134 Patterns of On-Demand Medication Use in the Treatment of Hereditary Angioedema Attacks: Implications for the Management of Hereditary Angioedema in the Emergency Department

Annals of emergency medicine, 2018-10, Vol.72 (4), p.S56-S56

2018

Volltextzugriff (PDF)

P160 LONG-TERM PROPHYLAXIS WITH SUBCUTANEOUS C1-INHIBITOR IN US PATIENTS WITH HEREDITARY ANGIOEDEMA AND VERY FREQUENT ATTACKS

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.S31-S31

2019

Volltextzugriff (PDF)

P161 ABSENCE OF BLOOD PRESSURE EFFECTS WITH SUBCUTANEOUS C1-INHIBITOR PROPHYLAXIS THERAPY IN PATIENTS WITH HEREDITARY ANGIOEDEMA

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.S31-S31

2019

Volltextzugriff (PDF)

EXPLORATORY ANALYSIS REVEALS POSITIVE CORRELATION BETWEEN C1 ESTERASE INHIBITOR AND SERUM COMPLEMENT 4 ANTIGEN LEVELS

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S34-S34

2018

Volltextzugriff (PDF)

LONG-TERM EFFICACY AND SAFETY OF SUBCUTANEOUS C1-INHIBITOR IN ELDERLY PATIENTS WITH HEREDITARY ANGIOEDEMA TYPE I/II

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S32-S32

2018

Volltextzugriff (PDF)

LONG-TERM EFFICACY OF SUBCUTANEOUS C1 INHIBITOR IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S31-S32

2018

Volltextzugriff (PDF)

OUTCOMES FOLLOWING USE OF SUBCUTANEOUS C1-INHIBITOR DURING PREGNANCY IN PATIENTS WITH HEREDITARY ANGIOEDEMA

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S31-S31

2018

Volltextzugriff (PDF)

P160 Indirect comparison of placebo-controlled trials of C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks

Annals of allergy, asthma, & immunology, 2017-11, Vol.119 (5), p.S41-S41

2017

Volltextzugriff (PDF)

EFFECTS OF SUBCUTANEOUS C1-ESTERASE INHIBITOR ON COAGULATION AND FIBRINOLYTIC PARAMETERS

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S32-S33

2018

Volltextzugriff (PDF)

P156 Use of rescue medication in hereditary angioedema attacks and its relation to attack severity

Annals of allergy, asthma, & immunology, 2017-11, Vol.119 (5), p.S40-S40

2017

Volltextzugriff (PDF)

Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled Trial

Cephalalgia, 2009-09, Vol.29 (9), p.921-927

2009

Volltextzugriff (PDF)

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2022-03, Vol.399 (10328), p.945-955

2022

Volltextzugriff (PDF)

Detection of Staphylococcus aureus within starter culture preparations containing Staphylococcus carnosus

Journal of food protection, 1994-11, Vol.57 (11), p.981-984

1994

Volltextzugriff (PDF)

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-04, Vol.401 (10382), p.1079-1090

2023

Volltextzugriff (PDF)

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

The New England journal of medicine, 2017-03, Vol.376 (12), p.1131-1140

2017

Volltextzugriff (PDF)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Allergy, asthma, and clinical immunology, 2019-08, Vol.15 (1), p.49-49, Article 49

2019

Volltextzugriff (PDF)

Long-term Safety of Subcutaneous C1-Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB39-AB39

2019

Volltextzugriff (PDF)

Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial

Allergy and asthma proceedings, 2018-09, Vol.39 (5), p.365

2018

Volltextzugriff (PDF)

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

The Lancet. Haematology, 2024-06, Vol.11 (6), p.e436-e447

2024

Volltextzugriff (PDF)

Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results

ClinicoEconomics and outcomes research, 2017-01, Vol.9, p.685-698

2017

Volltextzugriff (PDF)

Corrigendum to ‘Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 8: Nicotine Bridging – Estimating smoke constituent exposure by their relationships to both nicotine levels in mainstream cigarette smoke and in smokers’ [Regul. Toxicol. Pharmacol. 64 (2012) S85–S97]

Regulatory toxicology and pharmacology, 2015-03, Vol.71 (2), p.185-185

2015

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(9)
Female
(7)
Male
(7)
Adult
(6)
Angioedema
(6)
Edema
(6)
Patients
(6)
Angioedemas, Hereditary - Drug Therapy
(5)
Double-Blind Method
(5)
Prophylaxis
(5)
Treatment Outcome
(5)
Complement C1 Inhibitor Protein - Adverse Effects
(4)
Hereditary Angioedema
(4)
Thromboembolism
(4)
Young Adult
(4)
Adolescent
(3)
Allergy
(3)
Anaphylaxis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

134 Patterns of On-Demand Medication Use in the Treatment of Hereditary Angioedema Attacks: Implications for the Management of Hereditary Angioedema in the Emergency Department

P160 LONG-TERM PROPHYLAXIS WITH SUBCUTANEOUS C1-INHIBITOR IN US PATIENTS WITH HEREDITARY ANGIOEDEMA AND VERY FREQUENT ATTACKS

P161 ABSENCE OF BLOOD PRESSURE EFFECTS WITH SUBCUTANEOUS C1-INHIBITOR PROPHYLAXIS THERAPY IN PATIENTS WITH HEREDITARY ANGIOEDEMA

EXPLORATORY ANALYSIS REVEALS POSITIVE CORRELATION BETWEEN C1 ESTERASE INHIBITOR AND SERUM COMPLEMENT 4 ANTIGEN LEVELS

LONG-TERM EFFICACY AND SAFETY OF SUBCUTANEOUS C1-INHIBITOR IN ELDERLY PATIENTS WITH HEREDITARY ANGIOEDEMA TYPE I/II

LONG-TERM EFFICACY OF SUBCUTANEOUS C1 INHIBITOR IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA

OUTCOMES FOLLOWING USE OF SUBCUTANEOUS C1-INHIBITOR DURING PREGNANCY IN PATIENTS WITH HEREDITARY ANGIOEDEMA

P160 Indirect comparison of placebo-controlled trials of C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks

EFFECTS OF SUBCUTANEOUS C1-ESTERASE INHIBITOR ON COAGULATION AND FIBRINOLYTIC PARAMETERS

P156 Use of rescue medication in hereditary angioedema attacks and its relation to attack severity

Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled Trial

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Detection of Staphylococcus aureus within starter culture preparations containing Staphylococcus carnosus

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Long-term Safety of Subcutaneous C1-Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study

Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results

Suchergebnisse filtern